Jump to content

Evolocumab: Difference between revisions

From Wikipedia, the free encyclopedia
Browse history interactively
← Previous editNext edit →
Content deleted Content added
VisualWikitext
fixed dead link
ce
Line 109: Line 109:
}}
}}


'''Evolocumab'''<ref>{{cite journal | vauthors = ((World Health Organization)) | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 108 | journal = WHO Drug Information | volume = 26 | issue = 4 | year = 2012 | url =https://www.who.int/medicines/publications/druginformation/innlists/PL108.pdf | author-link = World Health Organization }}</ref> (trade name '''Repatha''') is a [[monoclonal antibody]] that is a [[immunotherapy]] medication for the treatment of [[hyperlipidemia]].
'''Evolocumab'''<ref>{{cite journal | vauthors = ((World Health Organization)) | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 108 | journal = WHO Drug Information | volume = 26 | issue = 4 | year = 2012 | url =https://www.who.int/medicines/publications/druginformation/innlists/PL108.pdf | author-link = World Health Organization }}</ref> (trade name '''Repatha''') is a [[monoclonal antibody]] that is an [[immunotherapy]] medication for the treatment of [[hyperlipidemia]].


Evolocumab is a fully human monoclonal antibody that inhibits [[PCSK9|proprotein convertase subtilisin/kexin type 9 (PCSK9)]]. PCSK9 is a protein that targets [[LDL receptor]]s for degradation; its inhibition thereby enhances the [[liver]]'s ability to remove [[LDL-C]], often simplistically referred to as "bad" [[Cholesterol embolism|cholesterol]], from the blood.<ref>{{cite journal | vauthors = Coppinger C, Movahed MR, Azemawah V, Peyton L, Gregory J, Hashemzadeh M | title = A Comprehensive Review of PCSK9 Inhibitors | journal = Journal of Cardiovascular Pharmacology and Therapeutics | volume = 27 | pages = 10742484221100107 | date = May 20, 2022 | pmid = 35593194 | doi = 10.1177/10742484221100107 | s2cid = 248918656 | doi-access = free }}</ref><ref>{{cite journal | vauthors = Weinreich M, Frishman WH | title = Antihyperlipidemic therapies targeting PCSK9 | journal = Cardiology in Review | volume = 22 | issue = 3 | pages = 140–146 | date = 2014 | pmid = 24407047 | doi = 10.1097/CRD.0000000000000014 | s2cid = 2201087 }}</ref>
Evolocumab is a fully human monoclonal antibody that inhibits [[PCSK9|proprotein convertase subtilisin/kexin type 9 (PCSK9)]]. PCSK9 is a protein that targets [[LDL receptor]]s for degradation; its inhibition thereby enhances the [[liver]]'s ability to remove [[LDL-C]], often simplistically referred to as "bad" [[Cholesterol embolism|cholesterol]], from the blood.<ref>{{cite journal | vauthors = Coppinger C, Movahed MR, Azemawah V, Peyton L, Gregory J, Hashemzadeh M | title = A Comprehensive Review of PCSK9 Inhibitors | journal = Journal of Cardiovascular Pharmacology and Therapeutics | volume = 27 | pages = 10742484221100107 | date = May 20, 2022 | pmid = 35593194 | doi = 10.1177/10742484221100107 | s2cid = 248918656 | doi-access = free }}</ref><ref>{{cite journal | vauthors = Weinreich M, Frishman WH | title = Antihyperlipidemic therapies targeting PCSK9 | journal = Cardiology in Review | volume = 22 | issue = 3 | pages = 140–146 | date = 2014 | pmid = 24407047 | doi = 10.1097/CRD.0000000000000014 | s2cid = 2201087 }}</ref>

Revision as of 23:51, 24 October 2023

Evolocumab
Monoclonal antibody
TypeWhole antibody
SourceHuman
TargetPCSK9
Clinical data
PronunciationEE-voh-lock-yoo-mab
Trade namesRepatha
Other namesAMG-145[1]
AHFS/Drugs.comMonograph
License data
Pregnancy
category
  • AU: B1
Routes of
administration		Subcutaneous
ATC code
Legal status
Legal status
  • AU: S4 (Prescription only)[2]
  • US: ℞-only[3]
  • In general: ℞ (Prescription only)
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
FormulaC6242H9648N1668O1996S56
Molar mass141790.89 g·mol−1

Evolocumab[4] (trade name Repatha) is a monoclonal antibody that is an immunotherapy medication for the treatment of hyperlipidemia.

Evolocumab is a fully human monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9). PCSK9 is a protein that targets LDL receptors for degradation; its inhibition thereby enhances the liver's ability to remove LDL-C, often simplistically referred to as "bad" cholesterol, from the blood.[5][6]

Mechanism

Evolocumab is designed to bind to PCSK9 and inhibit PCSK9 from binding to LDL receptors on the liver surface. In the absence of PCSK9, there are more LDL receptors on the surface of liver cells to remove LDL-C from the blood.[7]

History

Amgen submitted a biologics license application (BLA) for evolocumab to the FDA in August 2014.[8] The FDA approved evolocumab injection on 27 August 2015, for some patients who are unable to get their LDL cholesterol under control with current treatment options.[9] The European Commission approved it in July 2015.[10] Evolocumab received approval from Health Canada on September 10, 2015.[11] Amgen reported approval by Health Canada in a press release on September 15, 2015.[12]

Results of the FOURIER trial were published in March 2017.[13]

Regeneron Pharmaceuticals and Amgen had each filed for patent protection on their monoclonal antibodies against PCSK9 and the companies ended up in patent litigation in the U.S. In March 2016 a district court found that Regeneron's drug alirocumab infringed Amgen's patents; Amgen then requested an injunction barring Regeneron and Sanofi from marketing alirocumab, which was granted in January 2017. The judge gave Regeneron and Sanofi 30 days to appeal before the injunction went into effect.[14] After several years of litigation, the patent dispute between Regeneron and Amgen was docketed by the SCOTUS for March-April 2023[15] Numerous legal commentators were surprised by the SCOTUS decision, considering the existing trend not to review patent cases from the United States Court of Appeals for the Federal Circuit, since this court was created in 1982 to assure uniformity in patent law among all federal courts. The question before the US Supreme Court is "Whether enablement is governed by the statutory requirement, that the specification teach those skilled in the art to “make and use” the claimed invention, or whether it must instead enable those skilled in the art “to reach the full scope of claimed embodiments” without undue experimentation—i.e., to cumulatively identify and make all or nearly all embodiments of the invention without substantial “time and effort.”[15] Other commentators believe, that the SCOTUS took the case, because of the significance of the legal question, which is deemed comparable to the impact of KSR v. Teleflex.

Issued Amgen's patents have a so-called “functional genus claim,” which defines an antibody by its epitope, the specific target against which it binds. Although, Amgen did discover the target antigen, the antigen itself cannot be patented, because it is a product of nature (i.e. is was discovered rather than invented). However, Amgen was able to convince the USPTO to issue a patent, that broadly claims yet-unmade antibodies with a high affinity to the discovered antigen. Although there are many potential problems with such "functional genus" claims, the lower courts invalidated broad Amgen's claims based on the patent requirements for sufficiency of disclosure. The purposivism justification for disallowing such broad poorly-enabled claims is to allow other pharmaceutical companies to develop other (and potentially better) drugs, that target the same receptor. However, the drawback of such narrow interpretation, is the resulting reluctance of the antigen discoverers to share their finding with the World, because such early disclosure would prevent them from reaping the maximum profits from their discovery, which they could obtain by developing multiple medications, and keeping them secret for many years. [16] However, such dilemma is not unique to biologics or to pharmaceuticals, since the purpose of the patent system is to provide an incentive for earlier disclosure in the gambling game from-discovery-to-market, that does not necessarily reward every participant according to their contribution, but encourages discovers and inventors to play the gambling game nevertheless.[17]

Society and culture

Economics

In 2015 it cost about US$14,100 per year. One article calculated this to be about $400,000 to $500,000 per quality-adjusted life year (QALY), which did not meet "generally accepted" cost-benefit thresholds. The authors calculated that an annual cost of $4,500 would meet an acceptable $100,000 per QALY standard.[18] On October 26, 2018 the maker of the drug, Amgen, announced a 60% cut in price and the drug at that date cost $5,850 per year.[19]

References

  1. ^ Sheridan C (December 2013). "Phase 3 data for PCSK9 inhibitor wows". Nature Biotechnology. 31 (12): 1057–1058. doi:10.1038/nbt1213-1057. PMID 24316621. S2CID 34214247.
  2. ^ "Prescription medicines: registration of new chemical entities in Australia, 2015". Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 10 April 2023.
  3. ^ "Repatha- evolocumab injection, solution Repatha- evolocumab kit". DailyMed. U.S. National Library of Medicine. 6 May 2020. Retrieved 20 October 2020.
  4. ^ World Health Organization (2012). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 108" (PDF). WHO Drug Information. 26 (4).
  5. ^ Coppinger C, Movahed MR, Azemawah V, Peyton L, Gregory J, Hashemzadeh M (May 20, 2022). "A Comprehensive Review of PCSK9 Inhibitors". Journal of Cardiovascular Pharmacology and Therapeutics. 27: 10742484221100107. doi:10.1177/10742484221100107. PMID 35593194. S2CID 248918656.
  6. ^ Weinreich M, Frishman WH (2014). "Antihyperlipidemic therapies targeting PCSK9". Cardiology in Review. 22 (3): 140–146. doi:10.1097/CRD.0000000000000014. PMID 24407047. S2CID 2201087.
  7. ^ "PCSK9 инхибитори – нов клас медикаменти за лечение на дислипидемия" [PCSK9 inhibitors – a new class of drugs for the treatment of dyslipidemia]. Списание МД [MD Journal] (in Bulgarian). November 2016. Retrieved 2018-10-28 – via spisaniemd.bg.
  8. ^ "Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA". Amgen. 28 August 2014.
  9. ^ "FDA approves Repatha to treat certain patients with high cholesterol". FDA News Release. U.S. Food and Drug Administration. U.S. Food and Drug Administration. August 27, 2015. Retrieved 30 August 2015.
  10. ^ "European Commission Approves Amgen's New Cholesterol-Lowering Medication Repatha™ (evolocumab), The First PCSK9 Inhibitor To Be Approved In The World, For Treatment Of High Cholesterol". Amgen. 21 July 2015.
  11. ^ "Regulatory Decision Summary (SBD): REPATHA - 2015 - Health Canada". www.hc-sc.gc.ca. Archived from the original on 2015-10-07. Retrieved 2015-10-06.
  12. ^ "Amgen - Media - In The News". www.amgen.ca. Archived from the original on 2016-03-04. Retrieved 2015-09-17.
  13. ^ Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, et al. (May 2017). "Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease". The New England Journal of Medicine. 376 (18): 1713–1722. doi:10.1056/nejmoa1615664. hdl:10536/DRO/DU:30157496. PMID 28304224. S2CID 1972937.
  14. ^ Feeley J, Bloomfield D, Decker S (5 January 2017). "Amgen Wins Ban on Sanofi's Praluent Cholesterol Drug Sales". Bloomberg News.
  15. ^ a b "Amgen Inc. V. Sanofi". SCOTUSblog.
  16. ^ Holman CM (2022). "Amgen v. Sanofi: The Supreme Court Takes up the Enablement Requirement in the Context of Therapeutic Monoclonal Antibodies". Biotechnology Law Report. 41 (6): 269–282. doi:10.1089/blr.2022.29293.cmh. S2CID 254435116.
  17. ^ Tu SS, Nagar S, Van de Wiele VL (May 2023). "Broad Patent Claims Come Before the Supreme Court in Amgen v Sanofi". JAMA. 329 (19): 1641–1642. doi:10.1001/jama.2023.5638. PMID 36972066. S2CID 257765649.
  18. ^ Kazi DS, Moran AE, Coxson PG, Penko J, Ollendorf DA, Pearson SD, et al. (August 2016). "Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease". JAMA. 316 (7): 743–753. doi:10.1001/jama.2016.11004. PMID 27533159.
  19. ^ Goldman D. "The bigger message behind Amgen's decision to slash cost of its Repatha cholesterol drug". MarketWatch. Retrieved 2018-10-28.
  • "Evolocumab". Drug Information Portal. U.S. National Library of Medicine.
Retrieved from "https://en.wikipedia.org/enwiki/w/index.php?title=Evolocumab&oldid=1181747162"